Status:
NOT_YET_RECRUITING
Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow
Lead Sponsor:
Tata Memorial Centre
Conditions:
Diffuse Glioma
Glioblastoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Gliomas are common primary brain tumors in adults. Gliomas can be classified into different types based on tumor grade, histopathological features, and molecular characteristics. The common types of d...
Detailed Description
Glioblastoma multiforme (GBM) represents grade 4 diffuse gliomas accounting for the most common primary malignant central nervous system (CNS) tumors in adults . GBM is treated with radiotherapy (RT) ...
Eligibility Criteria
Inclusion
- Histological diagnosis of diffuse glioma. Patients with IDH-negative GBM (stratum A) and IDH-mutant glioma (astrocytoma or oligodendroglioma) need radiotherapy (stratum B).
- Age: 18-70 years. Karnofsky Performance Scale (KPS) ≥60
Exclusion
- Multifocal or multicentric disease Not eligible for radical intent radiation. IDH status is unknown or uninterpretable (IHC or gene sequencing). Use of prior radiotherapy to the head-neck region or brain or chemotherapy. Contraindication/unable to undergo MRI or PET scan during radiation.
Key Trial Info
Start Date :
November 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 30 2028
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06492486
Start Date
November 30 2025
End Date
July 30 2028
Last Update
September 16 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.